IREDA Q2 FY27: PAT flat YoY at ₹552 Cr as Gensol-driven provisioning compresses margins

IREDA's consolidated total income rose 14.0% YoY to ₹2,346.88 Cr (standalone ₹2,344.75 Cr, basis differs <0.4%), but consolidated PAT of ₹552.14 Cr was essentially flat YoY (+0.5% vs ₹549.33 Cr) — a sharp deceleration from the 14% revenue growth. The QoQ jump (+63.1% from Q1 FY27's ₹338.53 Cr) looks dramatic but is mean-reversion off a weak prior quarter rather than a trend acceleration; EPS at ₹1.97 is unchanged from a year ago on a flat equity base (₹2,809.23 Cr paid-up capital), confirming profit growth, not just share-count dilution, stalled. The story is margin compression on the lending book, not the topline. Net profit margin fell to 23.53% from 26.69% a year ago, and operating margin (total income less non-finance operating costs, our methodology) eased to roughly 88.7% from 93.29% YoY — though it did recover from Q1 FY27's 78.41%. Finance cost grew roughly in line with revenue (+13.6% YoY to ₹1,377.27 Cr), but impairment on financial instruments more than doubled to ₹187.70 Cr from ₹69.92 Cr YoY, the primary drag on profit growth. That impairment build coincides with the Stage-III provisioning coverage ratio rising sharply to 70.44% from 51.48% YoY, even as the net NPA ratio actually improved to 1.08% from 1.97% — a deliberately conservative provisioning stance rather than a deterioration in underlying asset quality. The provisioning build ties directly to this quarter's governance developments: at its 39th AGM on September 29, 2026 (within this reporting period per the event record), IREDA's board actions around the Gensol Engineering exposure (₹672.74 Cr, alongside a smaller Arjuna Biofuels case) drove the fraud reporting to RBI noted in both standalone and consolidated statements, with 100% ECL already provided. Management gives no formal quarterly guidance on record, and no press release commentary was available to cross-check against the print, so neither can be graded here. No Q2 FY27-specific consensus PAT estimate turned up in search; ICICI Direct's FY27E consolidated PAT estimate of ₹2,192 Cr (set ahead of Q1 FY27) implies H1 FY27's actual ₹890.67 Cr covers ~40.6% of the full-year number, meaning H2 needs to carry a larger share than usual — directionally consistent with a quarter that undershot normal profit cadence rather than beat it. Other period developments — the CMD's additional charge extension by three months (Oct 1) and the appointment of Shiv & Associates and MAPSS & Co. as joint statutory auditors for FY27 (Sep 25) — are procedural and don't bear on the numbers. The FY27 Performance MoU signed with MNRE (Oct 5) sets forward targets but was not available in enough detail to benchmark against this quarter's print.